These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36692919)

  • 1. International Experiences and Made-in-Canada "Social Pharmaceutical Innovations" as Responses to Challenges Facing Drugs for Rare Diseases.
    Douglas CMW
    Healthc Pap; 2023 Jan; 21(1):66-72. PubMed ID: 36692919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases.
    Douglas CMW; Aith F; Boon W; de Neiva Borba M; Doganova L; Grunebaum S; Hagendijk R; Lynd L; Mallard A; Mohamed FA; Moors E; Oliveira CC; Paterson F; Scanga V; Soares J; Raberharisoa V; Kleinhout-Vliek T
    Orphanet J Rare Dis; 2022 Sep; 17(1):344. PubMed ID: 36064440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific, Fair and Transparent: A Canadian Process for Funding Drugs for Rare Diseases.
    Stevenson H
    Healthc Pap; 2023 Jan; 21(1):28-33. PubMed ID: 36692913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
    Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
    Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can Managed Access Agreements Mitigate Evidentiary, Economic and Ethical Issues with Access to Expensive Drugs for Rare Diseases in the Canadian Context?
    McPhail M; Bubela T
    Healthc Pap; 2023 Jan; 21(1):59-65. PubMed ID: 36692918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canadians Need Improved Access to Drugs for Rare Diseases, Not More Denial.
    Rawson NSB; Adams J
    Healthc Pap; 2023 Apr; 21(2):4-10. PubMed ID: 37417343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Historical and projected public spending on drugs for rare diseases in Canada between 2010 and 2025.
    Lech R; Chow G; Mann K; Mott P; Malmberg C; Forte L
    Orphanet J Rare Dis; 2022 Oct; 17(1):371. PubMed ID: 36209128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons learned from the Canadian Fabry Disease Initiative for future risk-sharing and managed access agreements for pharmaceutical and advanced therapies in Canada.
    Douglas CMW; Grunebaum S
    Health Policy; 2024 May; 143():105044. PubMed ID: 38508062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to "Canadians Need Improved Access to Drugs for Rare Diseases, Not More Denial".
    Sirrs S; Jiwani B; Lun E; Nakagawa B; McFarlane A
    Healthc Pap; 2023 Apr; 21(2):11-12. PubMed ID: 37417344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paces of Costly Care: Rare Disease Drug Access in Canada.
    McGuire M
    Med Anthropol; 2020; 39(4):319-332. PubMed ID: 30892965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Orphan Drug Framework (ODF) for Canada.
    Lee DK; Wong B
    J Popul Ther Clin Pharmacol; 2014; 21(1):e42-6. PubMed ID: 24671833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Guest Editor's Response to "Canadians Need Improved Access to Drugs for Rare Diseases, Not More Denial".
    Lexchin J
    Healthc Pap; 2023 Jul; 21(3):70-71. PubMed ID: 37887173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
    Stafinski T; Glennie J; Young A; Menon D
    Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference survey.
    Dragojlovic N; Rizzardo S; Bansback N; Mitton C; Marra CA; Lynd LD
    Patient; 2015 Feb; 8(1):93-101. PubMed ID: 25586645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey.
    Polisena J; Burgess M; Mitton C; Lynd LD
    BMC Health Serv Res; 2017 May; 17(1):372. PubMed ID: 28549479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tackling rare diseases at European level: why do we need a harmonized framework?
    Taruscio D; Trama A; Stefanov R
    Folia Med (Plovdiv); 2007; 49(1-2):59-67. PubMed ID: 18018471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why orphan drug coverage reimbursement decision-making needs patient and public involvement.
    Douglas CM; Wilcox E; Burgess M; Lynd LD
    Health Policy; 2015 May; 119(5):588-96. PubMed ID: 25641123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases.
    Epps C; Bax R; Croker A; Green D; Gropman A; Klein AV; Landry H; Pariser A; Rosenman M; Sakiyama M; Sato J; Sen K; Stone M; Takeuchi F; Davis JM
    Ther Innov Regul Sci; 2022 Nov; 56(6):964-975. PubMed ID: 35471559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introducing Medical Assistance in Dying in Canada: Lessons on Pragmatic Ethics and the Implementation of a Morally Contested Practice.
    Frolic A; Oliphant A
    HEC Forum; 2022 Dec; 34(4):307-319. PubMed ID: 36053402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.